German company looking at Nitrous Oxide for TBI treatment

Randy Rozek • September 14, 2016

A company in Germany is in the process of creating a new drug aimed at treating patients who suffer traumatic brain injury( TBI).

According to Labiotech.eu, a website focused on biotech news, Vasopharm’s Nitrous Oxide Synthase inhibitor is starting Phase III.

Vasopharm is a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases and their consequences – indications with significant unmet clinical need. The company is focused on the development of therapeutics that steer the availability of biological nitric oxide (NO) over the entire NO signal cascade and its functional counterpart the NAD(P)H oxidase (NOX) family.

The company focuses on drug development in acute niche indications with an unmet medical need that enables it to rapidly demonstrate clinical efficacy. In addition to developing its own products to demonstrate clinical efficacy, Vasopharm is actively seeking complementary opportunities in the area of acute cardiovascular or CNS diseases preferably in late pre-clinical or early clinical state of development.

“The company has found NOS to be an effective target for treatments of traumatic brain injury( TBI); so successful that it has just enrolled its first patient in a Phase III clinical trial for Ronopterin,” the article reads. “Ronopterin inhibits NOS as an analogue of the natural co-factor, biopterin. It is thought to selectively down-regulate inducible NOS (iNOS) and stem the cascade of damaging sequellae set in motion by TBI. This cascade leads to 70,000 deaths and 100,000 disabilities annually, making TBI the leading cause of death and disability in young adults.”

Nitric oxide synthases are a family of enzymes catalyzing the production of nitric oxide (NO) from L-arginine. NO is an important cellular signaling molecule. It helps modulate vascular tone, insulin secretion, airway tone, and peristalsis, and is involved in angiogenesis and neural development. It may function as a retrograde neurotransmitter.

Free E-Books 
By Rozek Law Offices, S.C. • November 6, 2026
Deer car accident guide: what to do at the scene, what evidence to save, how insurance claims work, and when to get legal help.
By Rozek Law Offices, S.C. • October 26, 2026
Fall car accidents: what to do at the scene, what evidence to collect, and how insurance affects a claim—plus a Wisconsin car accident checklist.
By Rozek Law Offices, S.C. • October 22, 2026
School zone accident case study: what to do at the scene, how insurance reviews fault, and what evidence to save for a stronger claim.
By Rozek Law Offices, S.C • October 22, 2026
Work zone crash injury FAQs: steps to take, evidence to save, common mistakes, and when to get legal help after a construction-zone wreck.
By Rozek Law Offices, S.C. • October 9, 2026
Truck accident injury warning signs and what to do at the scene: protect evidence, handle insurance calls, and document symptoms for a claim.
By Rozek Law Offices, S.C. • September 18, 2026
UM UIM coverage FAQs for Wisconsin crashes: what it covers, what to do at the scene, insurance steps, and evidence to protect your claim.
By Rozek Law Offices, S.C. • September 11, 2026
Pedestrian accident claim steps in Wisconsin: what to do at the scene, handle insurance calls, and preserve evidence to support fair compensation.
By Rozek Law Offices, S.C. • August 14, 2026
brain injury claim documentation checklist: what to do after an accident, what to tell insurance, and how to save medical records and evidence.
By Rozek Law Offices, S.C. • July 17, 2026
Work zone crash claims: compare settlement vs trial, what to do at the scene, how insurance evaluates cases, and evidence that can strengthen recovery.
By Rozek Law Offices, S.C. • July 10, 2026
Fourth of July injury claims: what to do at the scene, how insurance reviews work, and what evidence to save to protect your personal injury case.